Daily Newsletter

16 August 2023

Daily Newsletter

16 August 2023

Avidity gains FDA orphan drug designation for DMD therapy

The Phase 1/2 EXPLORE44 study is currently assessing AOC 1044 as a treatment for individuals with DMD44.

RanjithKumar Dharma August 16 2023

Avidity Biosciences has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its AOC 1044 to treat Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44).

DMD is a rare, early-onset genetic condition that causes gradual muscle damage and weakness due to the loss of the dystrophin protein.

AOC 1044 provides phosphorodiamidate morpholino oligomers to skeletal muscles and cardiac tissue.

Its purpose is to selectively exclude exon 44 of the dystrophin gene, thereby facilitating the production of dystrophin.

The Phase 1/2 EXPLORE44 clinical trial is currently evaluating AOC 1044 as a treatment for individuals with DMD44. It marks the initial step in assessing a series of AOCs being developed by the company to address DMD.

Avidity intends to disclose findings from the EXPLORE44 trial's segment involving healthy volunteers in the fourth quarter of 2023. It is currently enrolling participants living with DMD44 in the trial.

In April 2023, the company secured fast-track designation from the FDA for AOC 1044 to treat DMD44.

Avidity chief medical officer Steve Hughes stated: “There are currently no treatment options that target the underlying cause of DMD44. AOC 1044 is designed to specifically skip exon 44 of the dystrophin gene to enable the production of functional dystrophin protein.

“We look forward to advancing AOC 1044 in clinical development and bringing this very important treatment to patients as quickly and safely as possible."

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close